The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer.
 
Esther N. Pijnappel
No Relationships to Disclose
 
Nienke P.M. Wassenaar
No Relationships to Disclose
 
Oliver J. Gurney-Champion
No Relationships to Disclose
 
Remy Klaassen
No Relationships to Disclose
 
Koen S. van der Lee
No Relationships to Disclose
 
Marjolein Pleunis- van Empel
No Relationships to Disclose
 
Dick J. Richel
No Relationships to Disclose
 
Marie-Cecile J C Legdeur
No Relationships to Disclose
 
Aart J. Nederveen
No Relationships to Disclose
 
Hanneke W.M. Van Laarhoven
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly/ImClone; Nordic Group; Servier
Research Funding - Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Nordic Group (Inst); Philips Healthcare (Inst); Roche (Inst); Servier (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Johanna Wilmink
Consulting or Advisory Role - Celgene; SERVIER; Shire
Research Funding - Amgen; AstraZeneca; Celgene; Halozyme; Merck; Novartis; Pfizer; Roche; SERVIER